Real World Data and the Management of Intracranial Hemorrhages (ICH) in Anticoagulated Patients

/

VIEW PROGRAM

This enduring activity was originally presented as a satellite symposium which was held during the 9th European Stroke Organisation Conference (ESOC) in Munich, Germany, in May 2023.

As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages (ICH), requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC-related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Recently, nationally recognized guidelines have provided clear direction for managing these major bleeding events. As data emerges regarding new approaches to therapy, clinicians need to be aware of these new and effective approaches and assess the benefits and risks associated with each of these approaches. This program focuses on managing ICHs, addresses patient treatment approaches, and distills essential information for everyday clinical practice.

  • Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience

  • Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)

  • Repletion Management for Vitamin K Antagonist Anticoagulation

  • Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence

  • Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy

  • Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding

  • Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH

  • Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing

  • Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH

  • Audience Q&A

Faculty:

Natalie Kreitzer, MD, MS
Associate Professor of Emergency Medicine, Department of Emergency Medicine
University of Cincinnati College of Medicine
Director of Stroke Services, West Chester Hospital
Cincinnati, Ohio

Adrian R. Parry-Jones, MD, FRCP, PhD
Geoffrey Jefferson Brain Research Centre
University of Manchester
Manchester, UK

David Seiffge, MD
Professor of Neurology
Department of Neurology, Inselspital University Hospital Bern
University of Bern
Bern, Switzerland

Moderator:
W. Brian Gibler, MD FACEP, FACC, FAHA
President, EMCREG-International
Professor of Emergency Medicine, Department of Emergency Medicine
University of Cincinnati College of Medicine
Cincinnati, Ohio